These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 11209999

  • 1. Renin-angiotensin system contribution to cardiac hypertrophy in experimental hyperthyroidism: an echocardiographic study.
    Basset A, Blanc J, Messas E, Hagège A, Elghozi JL.
    J Cardiovasc Pharmacol; 2001 Feb; 37(2):163-72. PubMed ID: 11209999
    [Abstract] [Full Text] [Related]

  • 2. [Contribution of the renin-angiotensin system to blood pressure variability in hyperthyroid rats].
    Basset A, Blanc J, Elghozi JL.
    Arch Mal Coeur Vaiss; 2000 Aug; 93(8):905-10. PubMed ID: 10989728
    [Abstract] [Full Text] [Related]

  • 3. [Renin-angiotensin system blocking agents reverse the myocardial hypertrophy in experimental hyperthyroid cardiomyopathy via altering intracellular calcium handling].
    Su L, Dai Y, Deng W, Yin YH.
    Zhonghua Xin Xue Guan Bing Za Zhi; 2008 Aug; 36(8):744-9. PubMed ID: 19100120
    [Abstract] [Full Text] [Related]

  • 4. The angiotensin type 1 receptor antagonist valsartan attenuates pathological ventricular hypertrophy induced by hyperhomocysteinemia in rats.
    Kassab S, Garadah T, Abu-Hijleh M, Golbahar J, Senok S, Wazir J, Gumaa K.
    J Renin Angiotensin Aldosterone Syst; 2006 Dec; 7(4):206-11. PubMed ID: 17318789
    [Abstract] [Full Text] [Related]

  • 5. Angiotensin II receptor antagonist TCV-116 induces regression of hypertensive left ventricular hypertrophy in vivo and inhibits the intracellular signaling pathway of stretch-mediated cardiomyocyte hypertrophy in vitro.
    Kojima M, Shiojima I, Yamazaki T, Komuro I, Zou Z, Wang Y, Mizuno T, Ueki K, Tobe K, Kadowaki T.
    Circulation; 1994 May; 89(5):2204-11. PubMed ID: 8181146
    [Abstract] [Full Text] [Related]

  • 6. Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study.
    Verma A, Meris A, Skali H, Ghali JK, Arnold JM, Bourgoun M, Velazquez EJ, McMurray JJ, Kober L, Pfeffer MA, Califf RM, Solomon SD.
    JACC Cardiovasc Imaging; 2008 Sep; 1(5):582-91. PubMed ID: 19356485
    [Abstract] [Full Text] [Related]

  • 7. Cardiovascular hypertrophy in diabetic spontaneously hypertensive rats: optimizing blockade of the renin-angiotensin system.
    Lassila M, Davis BJ, Allen TJ, Burrell LM, Cooper ME, Cao Z.
    Clin Sci (Lond); 2003 Apr; 104(4):341-7. PubMed ID: 12653675
    [Abstract] [Full Text] [Related]

  • 8. [Activation of the renin-angiotensin system and blood pressure variability in rats].
    Blanc J, Lambert G, Elghozi JL.
    Arch Mal Coeur Vaiss; 2000 Aug; 93(8):1019-22. PubMed ID: 10989749
    [Abstract] [Full Text] [Related]

  • 9. Renin angiotensin system-dependent hypertrophy as a contributor to heart failure in hypertensive rats: different characteristics from renin angiotensin system-independent hypertrophy.
    Sakata Y, Masuyama T, Yamamoto K, Doi R, Mano T, Kuzuya T, Miwa T, Takeda H, Hori M.
    J Am Coll Cardiol; 2001 Jan; 37(1):293-9. PubMed ID: 11153754
    [Abstract] [Full Text] [Related]

  • 10. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: I. Effects on left ventricular performance and neurohormonal systems.
    Spinale FG, de Gasparo M, Whitebread S, Hebbar L, Clair MJ, Melton DM, Krombach RS, Mukherjee R, Iannini JP, O SJ.
    Circulation; 1997 Oct 07; 96(7):2385-96. PubMed ID: 9337215
    [Abstract] [Full Text] [Related]

  • 11. Role of the renin-angiotensin system in cardiac hypertrophy induced in rats by hyperthyroidism.
    Kobori H, Ichihara A, Suzuki H, Takenaka T, Miyashita Y, Hayashi M, Saruta T.
    Am J Physiol; 1997 Aug 07; 273(2 Pt 2):H593-9. PubMed ID: 9277473
    [Abstract] [Full Text] [Related]

  • 12. Effects of angiotensin receptor blockade on haemodynamics and gene expression after myocardial infarction.
    Gurevich AK, Falk SA, Nemenoff RA, Weinberger HD, Summer SN, Rizeq M, Gengaro PE, Bedigian MP, Schrier RW.
    Drugs R D; 2002 Aug 07; 3(4):239-49. PubMed ID: 12455200
    [Abstract] [Full Text] [Related]

  • 13. Thyroxine-induced cardiac hypertrophy: influence of adrenergic nervous system versus renin-angiotensin system on myocyte remodeling.
    Hu LW, Benvenuti LA, Liberti EA, Carneiro-Ramos MS, Barreto-Chaves ML.
    Am J Physiol Regul Integr Comp Physiol; 2003 Dec 07; 285(6):R1473-80. PubMed ID: 12933361
    [Abstract] [Full Text] [Related]

  • 14. Effects of valsartan on left ventricular diastolic function in patients with mild or moderate essential hypertension: comparison with enalapril.
    Cuocolo A, Storto G, Izzo R, Iovino GL, Damiano M, Bertocchi F, Mann J, Trimarco B.
    J Hypertens; 1999 Dec 07; 17(12 Pt 1):1759-66. PubMed ID: 10658943
    [Abstract] [Full Text] [Related]

  • 15. Cardiac microvascular rarefaction in hyperthyroidism-induced left ventricle dysfunction.
    Freitas F, Estato V, Carvalho VF, Torres RC, Lessa MA, Tibiriçá E.
    Microcirculation; 2013 Oct 07; 20(7):590-8. PubMed ID: 23510303
    [Abstract] [Full Text] [Related]

  • 16. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: II. Effects on myocyte contractile processes.
    Spinale FG, Mukherjee R, Iannini JP, Whitebread S, Hebbar L, Clair MJ, Melton DM, Cox MH, Thomas PB, de Gasparo M.
    Circulation; 1997 Oct 07; 96(7):2397-406. PubMed ID: 9337216
    [Abstract] [Full Text] [Related]

  • 17. Neurohormonal activity and left ventricular geometry in patients with essential arterial hypertension.
    Muscholl MW, Schunkert H, Muders F, Elsner D, Kuch B, Hense HW, Riegger GA.
    Am Heart J; 1998 Jan 07; 135(1):58-66. PubMed ID: 9453522
    [Abstract] [Full Text] [Related]

  • 18. Renin-angiotensin system in thyroid dysfunction in rats.
    Marchant C, Brown L, Sernia C.
    J Cardiovasc Pharmacol; 1993 Sep 07; 22(3):449-55. PubMed ID: 7504137
    [Abstract] [Full Text] [Related]

  • 19. Angiotensin-(1-7) reduces cardiac effects of thyroid hormone by GSK3Β/NFATc3 signaling pathway.
    Senger N, Melo MB, Diniz GP, Campagnole-Santos MJ, Santos RAS, Barreto-Chaves MLM.
    Clin Sci (Lond); 2018 Jun 14; 132(11):1117-1133. PubMed ID: 29685981
    [Abstract] [Full Text] [Related]

  • 20. Cardiac ACE2/angiotensin 1-7/Mas receptor axis is activated in thyroid hormone-induced cardiac hypertrophy.
    Diniz GP, Senger N, Carneiro-Ramos MS, Santos RA, Barreto-Chaves ML.
    Ther Adv Cardiovasc Dis; 2016 Aug 14; 10(4):192-202. PubMed ID: 26715125
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.